This week: a viral vectors manufacturing technology has been patented, Cellar (CA, USA) and Organic cabaletta (PA, USA) completed an adoption program for technologies to automate the production of Autoleucel (Rese-Cel) on Cell Shuttle ™. More, XCELL Biosciences Australia (Xcellbio; Melbourne, Australia) and the Royal Perth Hospital (Australia) have joined forces to develop an automated manufacturing process for lymphocyte therapies infiltrating tumors (TIL).
The news highlights:
Patented viral vector technology
Cho plus (CA, USA) obtained a patent (patent n ° 12 252 713) covering a process of fusion and screening of cells in order to create cellular hybrids capable of producing viral vectors, which are essential tools for providing genes in gene therapy. This is in particular the first patent to cover the use of cellular hybrids for the production of viral vectors, potentially improving the efficiency and scalability of viral manufacturing vectors for therapeutic applications.
Larry Forman, founder of Cho Plus, CEO and co-inventor of this technology, said: “We are delighted to reach this step. Technology has been developed thanks to the hard work and creativity of our scientific staff. Certain current diseases are likely to generate gene therapy, but they remain unrealized due to high viral vectors production technology and possible technology.
Car-T manufacturing
Cellares finished its technology adoption program, which has tested its automated manufacturing platform shuttle could effectively produce the main candidate of the main Cabaletta Bio product. The results have succeeded, demonstrating that the platform could manufacture several lots of CD19 CD19 cell therapy with CD19 target simultaneously in an automated process. After this success, organic cells and cabaletta plan to extend their collaboration to produce clinical quality lots (CGMP) for the use of patients, moving to clinical and commercial manufacturing.
“Thanks to our partnership with Cellares, our teams have managed to carry out concept proof to automate the process of manufacturing cellular drug substances.
Manufacturing collaboration for therapies lymphocytes infiltrating tumors
XCELLBIO and ROYAL PERTH Hospital joined forces to develop an automated clinical manufacturing process for TIL therapies using the XCELLBIO AVATAR ™ system. This collaboration aims to rationalize manufacturing, allowing faster and more efficient production of powerful TIL therapies for the use of clinical trials. Thanks to the partnership, XCELLBIO scientists will work with the Royal Perth hospital team to develop a manufacturing workflow that meets the key objectives of the quality of cells, quantity and therapeutic power, ultimately supporting the hospital clinical trials for patients with cancer.
“The emerging therapeutic class of lymphocytes infiltrating tumors is incredibly exciting, especially for solid tumors.